A NUMBER of clinical and statistical observations led to the suggestion (Boyland, Wallace and Williams, 1955) that patients suffering from cancer of the bladder excrete carcinogenic substances in the urine. The investigation of Bonser, Bradshaw, Clayson and Jull (1956) and of Allen, Boyland, Dukes, Horning and Watson (1957) indicate that a number of ortho-aminophenols can induce cancer in experimenta lanimals. Two ortho-aminophenols, both metabolites of tryptophan, are normally present in urine and these substances, 3-hydroxyanthranilic acid and 3-hydroxykynurenine, have produced tumours when implanted in the bladders of mice (Allen et al, 1957). Both 3-hydroxyanthranilic acid and 3-hydroxykynure-
indicate that a number of ortho-aminophenols can induce cancer in experimenta lanimals. Two ortho-aminophenols, both metabolites of tryptophan, are normally present in urine and these substances, 3-hydroxyanthranilic acid and 3-hydroxykynurenine, have produced tumours when implanted in the bladders of mice (Allen et al, 1957) . Both 3-hydroxyanthranilic acid and 3-hydroxykynureTryptophan 3-hydroxykynurenine --3-hydroxyanthranilic Nicotinic nine were shown to be present in increased amounts in the urine of patients suffering from cancer of the bladder Williams, 1954, 1956 ). ortho -Aminophenols are usually excreted as sulphuric esters or as glucuronides in urine and these compounds would be expected to be inactive as carcinogens unless hydrolysed by enzymes. The carcinogen concentration would be dependent on the time which the urine remained in the bladder, on the concentration of ortho-aminophenol conjugates in the urine and on the urinary activity of the enzymes sulphatase and 8-glucuronidase (Fig. 1 ). The activity of both sulphatase and f6-glucuronidase in urine is raised in cancer of the bladder (Boyland, Wallace and Williams, 1955) should be prevented.
The present work deals with the urinary fi-glucuronidase activity of patients suffering from cancer of the bladder and the effect of treatment with fi-glucuronidase inhibitors on the enzyme activity. The inhibitors used are all derived from glucosaccharic acid, which have been previously shown to inhibit f,-glucuronidase in vitro (Karunairatnam and Levvy, 1949; Mills and Paul, 1949; and Levvy, 1952) . Saccharo-l: 4-lactone (glucosaccharo-l: 4-lactone) is the most effective inhibitor and the inhibitory action of saccharates used in these investigations is probably due to the 1: 4-saccharolactone which they contain or is produced from saccharate in the body. Saccharic acid is readily and reversibly converted to a mixture of saccharo-1: 4-lactone and saccharo-3: 6-lactone.
Saccharo-l: 4-lactone (II) is formed from saccharic acid (III) by loss of the elements of water. This dehydration reaction which is reversible gives the lactone (II) which has a structural resemblance to glucosiduronic acids ief. I). Glucosaccharo-l: 4-lactone is probably an active inhibitor of fi-glucuronidase because of this similarity in structure which allows it to occupy the enzyme centre which is concerned with f,-glucuronidase activity. (IV) which is also formed from saccharic acid and only differs from the 1: 4-lactone, in the position of hydroxyl groups is a poor inhibitor. (For formulae I to IV see page 585).
EXPERIMENTAL
The fi-glucuronidase activity is almost always increased in the urine of patients with cancer of the bladder and remains high in most cases even after the tumour has been removed (Boyland, Wallace and Williams, 1955) . The method of estimation has since been modified in the following ways-(a) A 20 per cent solution of thymol in benzene is used as a preservative as it is more effective than the benzene used in the original work. (b) The buffer concentration has been increased so that the activity of alkaline urine specimens (previously discarded) may also be estimated. The enzyme is unstable in strongly alkaline solution. The upper limit of the norma] range using this method is 1.2 units/ml. All f8-glucuronidase values are expressed as units of activity per ml. of urine.
The unit of activity is defined as being that which liberates 1 pg. of phenolphthalein per hour at 37°C. In all cases the total 24 hr. output of urine was collected and the test performed on a 1 ml. aliquot of this; the total 24 hr. volume being also quoted so that the total 24 hr. excretion may be calculated. All patients included have a history of more than 2 years of cancer. (Table I) . (c) Ammonium hydrogen saccharate.-Treatment of a patient with 10 g. per day of ammonium hydrogen saccharate (Fig. 3) produced a fall in ,J-glucuronidase activity of the urine. Treating 6 patients with 3-3 g. of ammonium hydrogen saccharate 3 times daily produced an average apparent inhibition of the ,-glucuronidase activity of 47 per cent (Table III) . (d) Glucosaccharolactone. -(1) A group of patients were treated with a boiled solution of saccharic acid which contains an equilibrium mixture of saccharic acid and 3: 6 and 1 : 4 saccharolactones, and received 1-3 g. of saccharo-1 : 4-lactone 3 times daily. The effect of this treatment on the urinary ,6-glucuronidase activity (Fig. 4 and Table IV) indicates that the mean inhibition of fl-glucuronidase activity is 92 per cent. 
DISCUSSION
The urinary /?-glucuronidase activities of patients who have been suffering from cancer of the bladder for some years are almost all raised above the corresponding value for normal subjects. The increased activity does not depend upon infection although, in a few cases infected by B. coli, this may play some part.
The enzyme is stable up to pH 9.0 and the method of estimation allows urine of pH less than this value to be used. The results are in agreement with those obtained previously (Boyland et al., 1955) using an earlier technique.
The urinary /6-glucuronidase activity of patients with cancer of the kidney (hypernephroma) is low compared with that of bladder cancer patients, the average value being within the normal range. Fishman and his co-workers have shown that cancer cells have a high ,-glucuronidase activity but the high urinary activity in cancer of the bladder cannot be due to the urine being in contact with malignant tissue as urine from patients with cancer of the kidney should also be rich in fl-glucuronidase. This evidence further supports the suggestion (Boyland et al., 1955) that the increased urinary enzyme concentration is probably derived from the blood, the amount of the enzyme depending both on the blood concentration and the degree to which the enzyme passes through the kidney. The relationship between the 8-glucuronidase activities of serum and urine of patients with cancer of varying sites is being investigated further.
Patients suffering from cancer of the bladder have been treated with gluco- The authors realise that to treat patients who have had cancer of the bladder with compounds which will reduce the concentration of carcinogenic agents in the urine, is probably to act too late. Because of the long lag between the application of the carcinogenic stimulus and the occurrence of the cancer, the first stimulus had probably taken effect before treatment began. This is, however, not certain and the reduction of carcinogens in the urine may reduce the chance of tumours developing. The tumours may, however, be dependent on the continued presence of the carcinogen in the way that the growth of kidney tumours, induced in hamsters with stilboestrol is dependent on the continued presence of stilboestrol (Horning, 1956) . If the tumours of the bladder were dependent on the urinary carcinogen then treatment with saccharo-l: 4-lactone could prevent growth of established tumours.
Bladder cancer caused by aromatic amines among men in the chemical industry is probably due to metabolites of the aromatic amines being hydrolysed by f/-glucuronidase in the urine to give aminophenols. Stringent precautions are now taken in the chemical industry to prevent exposure to the carcinogenic amines. In such factories, however, if accidents happen the carcinogenic effect of exposure of personnel should be reduced by administration of saccharo-l: 4-lactone immediately following the exposure and for four or five days. In such cases the treatment should prevent the liberation of the carcinogen in the urine.
SUMMARY
The in vivo effect of various derivatives of saccharic acid which are fl-glucuronidase inhibitors has been investigated; oral administration of 1 g. saccharo-1: 4-lactone every 6 hours decreases the enzyme activity in the urine by 90 per cent.
Treatment with saccharolactone should therefore reduce the liberation of free carcinogenic aminophenols in urine. Such treatment is recommended for men accidentally exposed to carcinogenic aromatic amines and is being tried in prophylactic treatment of patients who have had bladder cancers removed or destroyed.
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